BMS 986308
Alternative Names: BMS-986308Latest Information Update: 02 Oct 2021
At a glance
- Originator Bristol-Myers Squibb
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 21 Feb 2021 Preclinical trials in Unspecified in USA (unspecified route)
- 16 Feb 2021 Bristol-Myers Squibb plans to initiate phase I in Healthy volunteers in USA February 2021 (NCT04763226)